Chaoju Eye Care Holdings Limited (2219.HK)

Deep-Dive Research Report

Prepared 7 June 2026. Healthcare / Ophthalmic services. Listed on the Main Board of the Hong Kong Stock Exchange (stock code 2219), incorporated in the Cayman Islands, operations entirely in mainland China.

A note on "concalls." Chaoju is a Hong Kong-listed micro-cap that reports on a half-yearly cadence and does not host quarterly earnings calls with published transcripts. The five most recent reporting periods used throughout this report, with their primary disclosures (HKEX results announcements plus the investor-presentation decks the company posts to its IR site), are:

1. FY2025 annual results - board meeting and results announcement late March 2026 (released ~31 March 2026); annual report ~April 2026. (Most recent; within ~90 days of report date.)
2. H1 2025 interim results - announced 29 August 2025 (investor deck dated 2025-08-29).
3. FY2024 annual results - announced 26 March 2025.
4. H1 2024 interim results - announced 29-30 August 2024.
5. FY2023 annual results - announced late March 2024.

Where this report says "(H1 2025 results, Aug 29 2025)" or similar, it refers to the announcement/deck for that period, not a verbatim call transcript.

SECTION 1: WHAT THE COMPANY DOES

Chaoju runs eye hospitals and optical shops in China. If you live in Baotou, Hohhot, or a string of cities across northern China and the Yangtze River Delta, and you need cataract surgery, laser vision correction, a pair of glasses for a myopic child, or treatment for a diseased retina, Chaoju is one of the private clinics you would walk into. It owns and operates a network of 31 ophthalmic hospitals and 32 optical centers spread across seven provinces and autonomous regions, with roughly 1,100-plus inpatient beds. In FY2025 its hospitals handled more than 1.06 million outpatient visits and its optical centers saw more than 100,000 customers.

The business is built on a simple but durable observation: eyes go wrong in predictable ways across a lifetime, and most of those problems are fixable with a procedure or a product. Children get myopic and need correction and control (glasses, ortho-keratology lenses, atropine). Young adults want to be rid of their glasses and pay out of pocket for laser refractive surgery. Middle-aged people develop presbyopia and dry eye. Older people get cataracts, glaucoma, and retinal disease. Chaoju sells across that entire age curve, which gives it both self-pay "consumer" demand (refractive surgery, premium optical) and medically necessary, partly-reimbursed "basic" demand (cataract, retina, glaucoma).

The founding story matters because it explains why an eye-care chain of national ambition is headquartered in one of China's least glamorous industrial cities. The family's medical lineage runs back to 1921, when Zhang Xinghuan, a traditional Chinese medicine practitioner, opened a clinic called Zhonghetang. His descendant Zhang Chaoju built the modern ophthalmic predecessor in Baotou, Inner Mongolia, in 1988, and is regarded as the pioneer of modern eye care in the region. The company is named after him. The current chairman, Zhang Bozhou, is the founder's son, and the controlling block is held by the founder's children and a niece. This is a family-controlled regional champion that used a July 2021 Hong Kong IPO (raising roughly HK$1.5-1.6 billion) to fund an expansion out of its Inner Mongolian heartland into the rest of North China and, more aggressively, into the wealthier Yangtze River Delta.

The thing that makes the business hard to replicate is not a single technology - the surgical equipment (Zeiss femtosecond lasers, phacoemulsification machines, intraocular lenses) is bought from global suppliers and is available to anyone with capital. What is hard to replicate is the combination of (1) licensed, experienced ophthalmic surgeons, who are scarce and take years to train, (2) hospital licences and the grade accreditations that allow a facility to perform complex procedures and bill insurance, and (3) local brand trust, which in eye surgery is everything - patients do not shop on price for someone cutting into their eye. Chaoju's two Inner Mongolian flagships (Inner Mongolia Chaoju and Baotou Chaoju) are accredited Grade 3A (三级甲等) specialist hospitals, the top tier in China's hospital grading system, and Chifeng Chaoju is Grade 3B. That accreditation is a multi-year regulatory achievement that a new entrant cannot buy.

A concrete walk-through. A 12-year-old in Hohhot is becoming myopic. The parents bring her to a Chaoju optical center, where an optometrist runs a refraction and axial-length measurement, then fits her with orthokeratology (overnight hard contact) lenses to slow the progression - a recurring, self-pay relationship that brings the family back for follow-ups and replacement lenses. Twenty years later that same patient, now an adult, returns to a Chaoju hospital for SMILE laser surgery to eliminate her glasses entirely, paying several thousand renminbi out of pocket. Decades after that, she comes back for cataract surgery, where the procedure and a basic intraocular lens are partly covered by medical insurance, with an option to pay up for a premium multifocal lens. One patient, three transactions across a lifetime, two of them self-pay - that lifecycle is the business.

SECTION 2: BUSINESS SEGMENTS

Chaoju reports two segments, which are roughly equal in size and represent two fundamentally different demand types: discretionary self-pay versus medically necessary and partly reimbursed.

2.1 Consumer Ophthalmic Services (~51% of revenue)

What it does. This is the elective, out-of-pocket side of the business. It bundles refractive surgery (laser vision correction to remove the need for glasses - LASIK and, increasingly, the flapless SMILE and SMILE Pro procedures), presbyopia correction, myopia prevention and control for children (orthokeratology lenses, defocus spectacles, atropine), dry-eye treatment, oculoplastic (cosmetic and functional eyelid/orbital) work, and the optical retail business - eye exams and the sale of spectacles and contact lenses through the 32 optical centers. The customer is paying cash for a lifestyle or appearance benefit, not because insurance is forcing a procedure.

The core capability. The skill here is consumer-facing: building trust and brand at the city level, running a high-throughput refractive surgery operation with the latest femtosecond laser platforms, and operating retail optical at scale. In FY2025 the optical centers' per-customer value rose 12.7% to about RMB 978, and average outpatient spend rose 4.3% to about RMB 797 - the company is pushing customers toward higher-value services and products rather than chasing volume on price. The deployment of five SMILE Pro systems is the visible edge of this: SMILE Pro is a premium, faster refractive platform that commands a higher price and signals technological currency to image-conscious young patients.

Why it exists as its own segment. It has completely different economics from basic care. Demand is discretionary and therefore cyclical with consumer confidence; pricing is set by the market, not by the state; and it competes head-on with the national chains (Aier in particular) on brand and price rather than on hospital licensing. It is the margin and growth ambition of the group, but also the segment most exposed to China's weak post-2024 consumer sentiment and to price wars in refractive surgery.

Competitive position. This is where Chaoju is most exposed. Refractive surgery is a national, marketing-driven business, and Aier Eye Hospital is everywhere with deeper pockets and a larger surgeon base. Chaoju wins where it has incumbent brand density (Inner Mongolia, parts of North China) and loses where it is a late entrant fighting for share in a crowded Tier-1/Tier-2 market. In FY2025 consumer revenue slipped slightly (about -4.6% in H1) under price competition and soft discretionary demand.

2.2 Basic Ophthalmic Services (~48-49% of revenue)

What it does. This is medically necessary eye care: cataract surgery (the single largest line), glaucoma, retinal and ocular fundus disease, strabismus (squint), ocular-surface and corneal disease, orbital disease, and pediatric ophthalmology. Much of it is partly covered by China's medical insurance system, so demand is far less discretionary - a cataract that is blinding someone gets treated regardless of the economy.

The core capability. This is the clinically deepest part of the business and the hardest to enter. It requires Grade 3A/3B hospital accreditation, complex surgical competence (vitreoretinal surgery in particular is a high-skill specialty), and the surgeon bench to staff it. Chaoju's flagship Grade 3A hospitals anchor this segment and act as referral and training hubs for the smaller hospitals in the network.

Why it exists as its own segment. Different demand driver (disease and ageing, not lifestyle), different payer (insurance, not the patient's wallet), and a different regulatory exposure - it is the segment hit by the government's volume-based procurement (集采) of intraocular lenses and by medical-insurance pricing reform on cataract IOLs, which compressed the per-procedure revenue on cataract work in 2024-2025. Management offset this by raising patient throughput and per-patient contribution. In FY2025 basic ophthalmic revenue was the relatively more resilient line (it grew 6.7% in FY2024), reflecting its non-discretionary nature, though it too softened in H1 2025 under the IOL pricing reset.

Competitive position. Here Chaoju competes less with the consumer chains and more with public tertiary eye hospitals (Beijing Tongren, the Zhongshan Ophthalmic Center in Guangzhou) for complex cases, and with local public general hospitals for routine cataract work. Its edge is being a dedicated, accredited specialist with shorter wait times than overloaded public hospitals, in regions where the top public eye centers are far away.

Segment summary

SECTION 3: PRODUCTS AND BUSINESS DETAIL

The catalogue. On the consumer side: laser refractive surgery (LASIK, femtosecond LASIK, SMILE and the newer SMILE Pro for the higher-end self-pay myope who wants to be glasses-free); ICL (implantable contact lens) for high myopes unsuitable for laser; presbyopia correction; orthokeratology lenses and other myopia-control products for children, a recurring-revenue line because lenses are replaced and follow-ups are frequent; dry-eye therapy; oculoplastic procedures; and full optometry plus spectacle and contact-lens retail through the optical centers. On the basic side: cataract phacoemulsification with intraocular lens implantation (standard and premium multifocal/toric IOLs), glaucoma medical and surgical management, vitreoretinal surgery and medical retina (including treatment for diabetic retinopathy and macular disease), strabismus correction, corneal and ocular-surface disease, orbital surgery, and pediatric ophthalmology.

What makes it hard. Three gating factors. First, clinical licensing: ophthalmic surgeons require years of training and are a scarce resource that the company must recruit, retain, and grow internally - the chain model only works if you can staff each new hospital with credible surgeons. Second, hospital accreditation: the Grade 3A/3B designations on the flagship hospitals took years to earn and unlock the ability to perform complex surgery and to bill insurance at higher tiers; new builds start lower-graded and must climb. Third, equipment and process: top-tier refractive surgery requires expensive femtosecond laser platforms (the SMILE Pro systems), and cataract and retinal surgery require capital-intensive operating suites - the capability is buyable with money but only operable with the surgeons in point one.

The delivery model. Chaoju runs a hub-and-spoke network. The Grade 3A flagships in Inner Mongolia (Inner Mongolia Chaoju, Baotou Chaoju) act as clinical centers of excellence, training grounds, and referral destinations for complex cases. Smaller hospitals and the optical centers feed the system, handle routine work, and capture consumer demand at the neighborhood level. New nodes are added two ways: greenfield builds and, increasingly, acquisitions of existing local eye hospitals and clinics, which buy an installed patient base and licences faster than building from scratch.

Geographies. The company spans seven provinces and autonomous regions. Its core and most profitable territory is Inner Mongolia (Baotou, Hohhot, Chifeng and surrounds), where it has dominant brand share and the strongest competitive moat. Around that core it pursues a two-pronged regional strategy that management describes as "consolidate North China, break through the Yangtze River Delta" (华北巩固 + 长三角突破). North China includes its expansion into Beijing (the acquisition of the Beijing Mingyue ophthalmic clinic) and surrounding Hebei/Shanxi-type markets; the Yangtze River Delta push targets the wealthier, higher-paying coastal provinces (Zhejiang, Jiangsu) where consumer ophthalmic demand and ability-to-pay are highest, but where it is a challenger brand against entrenched competitors.

Milestones that changed the business. The 1988 founding in Baotou; the July 2021 Hong Kong IPO that gave it acquisition capital; the run of acquisitions from 2022 onward (eight hospitals and two optical centers added between June 2022 and June 2023, most via M&A); the entry into Beijing; the Grade 3A accreditations of the two Inner Mongolian flagships; and the SMILE Pro rollout. The network grew from 26 hospitals / 27 optical centers (mid-2023) to 31 hospitals / 32 optical centers by FY2025.

SECTION 4: CUSTOMERS

Who buys. Individual patients, full stop. There is no enterprise customer, no government procurement contract, no concentration risk from a single buyer. Revenue is the aggregate of hundreds of thousands of individual visits. The customer base is split between self-pay consumers (refractive surgery patients, parents buying myopia control for children, optical retail shoppers) and patients receiving medically necessary, partly-reimbursed care (cataract, retina, glaucoma).

Who makes the decision and how. For consumer ophthalmic, the decision-maker is the patient or the parent, and the buying criteria are trust, surgeon reputation, technology (is this the latest laser?), safety record, and - secondarily - price. The sales cycle for refractive surgery is short (weeks of consideration) and marketing-driven. For myopia control in children, the optometrist's recommendation drives the initial purchase and then converts into a recurring follow-up relationship. For basic ophthalmic care, the "decision" is often a referral or a diagnosis - a patient with a cataract or retinal bleed needs treatment, and the choice is which hospital, decided on proximity, wait time, accreditation, and whether insurance is accepted.

Why they choose Chaoju. In its home regions, brand and incumbency: Chaoju has been the name in eye care in Inner Mongolia for decades, and in eye surgery patients overwhelmingly choose the trusted local name over a cheaper unknown. Against overloaded public hospitals, the draw is shorter waits and dedicated specialist focus. Against other private chains in contested markets, the pitch is accreditation (Grade 3A credibility) plus current technology.

Switching costs. For a one-off procedure like cataract surgery, switching cost is essentially zero at the point of purchase - it is a one-time decision driven by trust and access. The stickier relationships are myopia control for children (recurring follow-ups, a multi-year relationship with one clinic) and the broader lifecycle effect, where a satisfied refractive patient returns for cataract surgery decades later. There is no contractual lock-in; the moat is reputational and geographic, not contractual.

Concentration and contract structure. Customer concentration is negligible (atomized individual patients), which is a strength - no single customer can walk away and dent revenue. The flip side is that there are no long-term contracts and almost no recurring contractual revenue; the business must re-win demand every period through marketing, reputation, and referral. Revenue predictability therefore depends on regional brand strength and on the macro consumer environment for the discretionary half, and on disease/ageing demographics plus insurance policy for the non-discretionary half. The single largest "contract" relationship that matters is with the state payer - the medical-insurance system - which sets reimbursement and procurement terms for cataract IOLs and other basic procedures, and which has been squeezing those terms.

SECTION 5: COMPETITIVE LANDSCAPE

Chinese private ophthalmology is a real industry with several listed players, and it is dominated by one giant. The structure is: one national behemoth (Aier), a handful of mid-size national or super-regional chains, a long tail of local hospitals, and the public tertiary eye hospitals that own the top of the clinical pyramid.

Aier Eye Hospital (300015.SZ) is the elephant. By end-2024 it ran roughly 352 ophthalmic hospitals and 229 clinics across China and is the largest ophthalmology hospital group in the world. It competes nationally on brand, scale, surgeon depth, and marketing spend, and it is present in essentially every market Chaoju wants to enter. Chaoju's hospital arm is a fraction of Aier's size. Chaoju's defense is regional density and incumbency in Inner Mongolia and North China, where being the trusted local name beats a national brand's marketing budget; its vulnerability is in new contested markets (the Yangtze River Delta) where Aier is already entrenched.

Chengdu Pu Rui / Puri Eye (普瑞眼科, 301239.SZ) and Liaoning He Eye (何氏眼科, 301103.SZ) are mid-size listed chains - Puri national-urban in focus, He Eye anchored in the Northeast. They are closer in size to Chaoju and compete for the same Tier-2/Tier-3 expansion opportunities. C-MER (希玛眼科, 3309.HK) is a Hong Kong / Greater Bay Area-focused private group, geographically distinct from Chaoju's northern footprint but a peer in business model. Guangzheng Eye (光正眼科, 002524.SZ) is another listed private operator. At the top of the clinical hierarchy sit public tertiary eye hospitals - Beijing Tongren, the Zhongshan Ophthalmic Center (Sun Yat-sen University) - which dominate complex cases and research and set the clinical benchmark, but do not chase consumer/retail demand the way the private chains do.

Barriers to entry are moderate and uneven by segment. Capital is not the barrier (equipment is purchasable). The real barriers are surgeon availability, hospital licensing and grade accreditation, and local brand trust - the last of which is the most durable. A well-funded entrant can build a hospital in 18 months but cannot manufacture the decades of reputation that make a patient choose them for eye surgery. This is why expansion in the industry happens disproportionately through acquisition of existing local hospitals rather than greenfield.

Where Chaoju is strong: deep, defensible incumbency in Inner Mongolia and parts of North China; Grade 3A accreditation; a clean balance sheet (net cash) that funds M&A without leverage stress; and a disciplined, high-payout capital-return posture unusual for a growth-stage healthcare name. Where it is exposed: it is a regional player trying to grow in markets owned by a much larger national rival; its discretionary consumer segment is squeezed by both price competition and weak Chinese consumer sentiment; and its basic segment is exposed to state procurement and reimbursement policy.

Market caps are peer-size references only, sourced from public quotes around the dates shown, and move daily.

SECTION 6: INDUSTRY

What drives demand. Four structural forces, all favorable over a decade horizon. First, ageing - China's over-60 population is growing fast, and cataract and retinal disease are diseases of ageing; cataract is the single largest surgical eye procedure and grows with the demographic. Second, the juvenile myopia epidemic - a very high share of Chinese schoolchildren are myopic, creating durable demand for myopia-control products and, eventually, refractive surgery. Third, rising incomes and willingness to pay for elective vision correction and premium optical, which drives the discretionary consumer segment. Fourth, private-sector penetration - public hospitals are congested, and private chains are expanding into Tier-2 and Tier-3 cities with modern, turnkey eye-care facilities, taking share of a growing pie.

Size and growth. China's ophthalmic services market is large and growing at a mid-single-digit rate by some estimates (one third-party estimate puts the ophthalmic service market at roughly US$1.1bn in 2024 rising to ~US$1.6bn by 2031, ~4.9% CAGR; the broader ophthalmic devices market is larger, ~US$3.3bn in 2025, growing ~7% a year). Within it, cataract is the biggest disease segment and myopia/refractive the fastest-growing consumer category. These figures vary widely by source and methodology and should be read as directional, not precise.

Where Chaoju sits in the chain. Chaoju is a service provider (the hospital/clinic operator), at the customer-facing end of the chain. Upstream are the device and IOL makers (Zeiss, Alcon, Bausch + Lomb, and domestic IOL manufacturers) from whom Chaoju buys; Chaoju does not manufacture. Its value-add is clinical delivery, accreditation, brand, and access - not technology development.

Regulation and policy. This is the most important industry variable for the basic segment. China has rolled out volume-based procurement (集采) of intraocular lenses and medical-insurance pricing reform on cataract services, which cut the price of IOLs and the reimbursed price of cataract procedures. For providers this compresses per-procedure revenue (offset partially by higher volumes as cheaper IOLs expand access). On the consumer side, regulation is lighter, but the government's national myopia-prevention agenda is a tailwind for myopia-control demand. Hospital accreditation and licensing are the other regulatory gates.

Cyclicality. The business is two-natured. The basic/insurance segment is essentially non-cyclical (disease does not wait for the economy). The consumer/self-pay segment is meaningfully cyclical with consumer confidence - elective refractive surgery and premium optical purchases get deferred in downturns. China's soft consumer environment since 2024 is the live headwind, visible in Chaoju's flat-to-down consumer revenue and overall ~3% FY2025 revenue decline.

Net. Long-term demographic and penetration tailwinds are strong; near-term headwinds are real - state pricing pressure on cataract/IOL economics, refractive price competition, and weak discretionary spending.

SECTION 7: GROWTH TRIGGERS

Drawn from the five most recent results announcements / investor presentations. Forward-looking items only.

• Yangtze River Delta breakthrough (长三角突破). Management has repeatedly framed expansion into the wealthier Zhejiang/Jiangsu coastal markets as a core growth pillar, via both new builds and acquisitions. (Repeated across FY2024 results Mar 26 2025, H1 2025 results Aug 29 2025, and FY2025 results ~Mar 2026.)

• North China consolidation (华北巩固), including Beijing. Deepening density in the home and adjacent northern markets and integrating the Beijing clinic acquisition (Beijing Mingyue). (Repeated across FY2024 and FY2025 results.)

• Network expansion via M&A plus greenfield. Continued addition of eye hospitals and optical centers; the network reached 31 hospitals / 32 optical centers by FY2025 and management has guided to continued expansion of the key-region network. (FY2025 results ~Mar 2026; H1 2025 results Aug 29 2025.)

• SMILE Pro premium refractive rollout. Deployment of five SMILE Pro systems to upgrade the high-end refractive offering and lift consumer ASP. (FY2025 results ~Mar 2026.)

  Management positioned the premium-refractive and per-patient-value strategy as the lever to offset price competition, citing optical-center per-customer value up 12.7% to ~RMB 978 and average outpatient spend up 4.3% to ~RMB 797 (H1 2025 / FY2025 results).

• Per-patient value (ASP) uplift to offset price/procurement pressure. Explicit strategy of raising per-customer contribution through service-mix upgrades and premium products rather than chasing low-price volume, to counter IOL procurement and refractive price competition. (Repeated H1 2025 results Aug 29 2025 and FY2025 results ~Mar 2026.)

• Consumer ophthalmic deepening. Broadening the scope of consumer services (presbyopia, myopia control, dry eye, oculoplasty) as a margin and growth focus. (FY2025 results ~Mar 2026, listed among the three strategic priorities alongside North China/YRD geography and ESG.)

• Capacity / capability building via remaining IPO proceeds. As of late-Aug 2025 about HK$533m of IPO proceeds remained unutilized, earmarked for deployment by end-2027 - funding for the build/acquire pipeline is already in hand. (FY2025 annual report ~Apr 2026.)

• Grade-3A flagship leverage. The Grade 3A accreditation of the Inner Mongolia and Baotou flagships (and Grade 3B at Chifeng) supports higher-acuity case mix and referral capture. (FY2025 results ~Mar 2026.)

SECTION 8: KEY RISKS

• IOL volume-based procurement and cataract pricing reform. This is the live, named risk. China's centralized procurement of intraocular lenses and the medical-insurance pricing reset cut the price of IOLs and the reimbursed price of cataract procedures. Mechanism: cataract is the largest basic-segment line; lower per-procedure revenue compresses the segment unless volume growth fully offsets it. Management explicitly attributed part of the FY2025 ~3.2% revenue decline to "国家医疗保险服务定价改革及集采" (medical-insurance pricing reform and procurement) on IOLs. High-probability, moderate-and-ongoing drag rather than a catastrophic one.

  In its FY2025 commentary management tied the revenue decline directly to "intensified price competition" and the IOL "medical-insurance pricing reform and centralized procurement" - i.e., it is naming the headwind itself, not denying it.

• Refractive price war and weak consumer demand. The consumer segment is discretionary and contested. Mechanism: Aier and other chains cut refractive prices to win volume; in a soft consumer economy patients defer elective surgery; Chaoju's consumer revenue fell modestly in FY2025. High-probability, moderate drag tied to the macro cycle - it eases when Chinese consumer confidence recovers and worsens if it does not.

• Expansion execution and integration risk. Growth depends on building and acquiring hospitals outside the home turf, especially in the competitive Yangtze River Delta. Mechanism: new hospitals lose money before they mature; acquired hospitals can underperform or be overpaid for; the company is a challenger brand in those markets without its Inner Mongolian incumbency advantage. Moderate-probability, moderate-magnitude - a drag on returns if the expansion does not season into profitability, but the net-cash balance sheet limits the financial danger.

• Surgeon recruitment and key-person dependence. The model scales only if Chaoju can staff each new hospital with credible surgeons, a scarce resource. Mechanism: a shortage of qualified ophthalmic surgeons caps how fast it can expand and how well new sites perform. Persistent structural constraint, low-drama but real.

• Reputational / clinical-incident risk. In eye surgery, a single high-profile adverse outcome or malpractice scandal can damage the local brand that is the company's core asset, and brand is exactly what makes patients choose them. Low-probability, potentially high-impact at the regional level.

• Family control and governance. The founding family controls the company. Mechanism: minority interests depend on the family continuing to treat outside shareholders well; capital-allocation and related-party decisions sit with insiders. Mitigant in practice so far: the high dividend payout and buybacks suggest alignment with minority holders, and the company carries net cash with low leverage. Low-probability concern, worth monitoring (note the recurring use of cash for wealth-management products and a separate financial portfolio, which is a mild capital-allocation flag).

• Geographic concentration. A large share of profitability still comes from Inner Mongolia. Mechanism: a regional economic shock, a local policy change, or new competition in the home market would hit disproportionately. Moderate over time as the network diversifies, but real today.

SECTION 9: WALK THE TALK

The five reporting periods assessed: FY2023 results (~Mar 2024), H1 2024 results (Aug 29-30 2024), FY2024 results (Mar 26 2025), H1 2025 results (Aug 29 2025), and FY2025 results (~Mar 2026). The most recent is within ~90 days of this report. Because Chaoju does not host transcribed earnings calls, the "promises" assessed here are drawn from results-announcement commentary and investor decks rather than spoken Q&A, so the granularity is lower than for a US filer - this is disclosed rather than papered over.

The through-line across all five periods is a management team that has been consistent and broadly honest in framing, conservative in tone, and reliable on capital returns, while the operating results have softened against a tougher industry backdrop than the early post-IPO growth implied.

Start with the early period. Coming out of FY2023 and into H1 2024, the company was still showing the strong post-COVID rebound - in the earlier post-IPO phase revenue and profit had grown roughly 30% and 44% in a half-year, and the strategy was unambiguously growth-and-acquisition: expand the network, push into North China and the Yangtze River Delta. Management delivered on the network promise concretely - the hospital count rose from 26 (mid-2023) to 31 by FY2025, and optical centers from 27 to 32, with the Beijing clinic acquisition executed. On the stated geographic strategy ("consolidate North China, break through the Yangtze River Delta"), repeated at FY2024, H1 2025, and FY2025, they have done what they said in terms of footprint - the network did extend in those directions. That is a kept promise on inputs.

Where the picture is more mixed is on what that expansion translated into financially. By the FY2024 results (Mar 2025), the early hyper-growth had clearly faded: full-year profit was down year-on-year even as revenue edged up, and management began emphasizing per-patient value and cost discipline (selling and distribution expenses were cut materially) rather than headline growth. The honest read is that management pivoted the narrative in step with reality - they stopped promising growth they could not deliver into a price-competitive, procurement-pressured market, and instead guided toward ASP uplift and efficiency.

Across FY2024 and FY2025, management consistently attributed softness to external factors it had flagged - "intensified price competition" and IOL "medical-insurance pricing reform and centralized procurement." It set the expectation that ASP improvement and throughput would offset, rather than promising the headwind away.

Did the offset work? Partially. The ASP metrics they guided toward did materialize - outpatient average spend up 4.3% and optical per-customer value up 12.7% in the H1 2025 / FY2025 disclosures - so the specific operational promise (lift per-patient value to counter pricing pressure) was kept. But it was not enough to hold total revenue flat: FY2025 revenue still fell about 3.2% and profit slipped. So the strategy was executed as described, but the macro and policy headwinds were stronger than the offsets. That is closer to "honest but in a hard environment" than to "overpromised."

On capital returns, management has been not just consistent but better than its early guidance might have implied. It has paid a high and rising dividend through the slowdown (the FY2025 final dividend more than doubled the prior year's final), and it added buybacks. For a growth-stage healthcare company to return capital aggressively while its profit was declining is a credibility-positive signal - it shows the cash generation is real and the balance sheet is genuinely net cash, not financial-engineering optics.

The one watch-item is capital allocation outside the core: the recurring use of cash for wealth-management products and a financial-investment portfolio sits slightly awkwardly with a company still telling shareholders it has a multi-year expansion pipeline (and undeployed IPO proceeds). It is not a broken promise, but it is a place where "deploy capital into the highest-return eye-care opportunities" and "park cash in wealth-management products" are in mild tension.

Assessment. This is management that largely does what it says on the things within its control (network build, ASP strategy, capital returns) and is candid about the external pressures it cannot control. It did not overpromise growth into a deteriorating market; it adjusted the story honestly. The gap between input delivery (footprint, ASP) and output delivery (revenue/profit) is attributable to industry headwinds it flagged in advance rather than to spin. Credible, conservative, shareholder-aligned - with capital allocation into financial products the one item to keep an eye on.

SECTION 10: SHAREHOLDER FRIENDLINESS INDEX

Dividends. Chaoju is a genuine dividend payer with a high payout ratio, unusual for a growth-stage Chinese healthcare name. For FY2025 the board proposed a final dividend of HK$0.2423 per share, more than double the prior year's final of HK$0.1193, taking total FY2025 distributions to roughly HK$171m at a payout ratio of around 90%-plus of earnings. FY2024's full-year dividend was around HK$0.25 per share at roughly an 80% payout, and the company paid dividends in FY2023 as well. The trend is high and rising even as profit declined, which tells you the payout is funded by real, strong operating cash flow (FY2025 operating cash flow was about RMB 340m) and a net-cash balance sheet (year-end cash ~RMB 516m, asset-liability ratio ~20%, no gearing). The high payout against falling earnings is the notable feature: management is choosing to return cash rather than hoard it, which is shareholder-friendly, though a payout near or above ~90% of earnings leaves less internal headroom if the slowdown deepens.

Buybacks and dilution. The company has been buying back and cancelling shares - a genuine return, not just offsetting option dilution. Per the FY2025 disclosures, Chaoju repurchased and cancelled about 1.85 million shares during 2025 (at HK$2.53-2.75), plus a further ~2.33 million shares shortly after year-end (late 2025 into early 2026). The MoatMap database (the source for the trailing ~90 days; ⚠ last scraped 2026-06-06, ~37h stale) shows the program continuing into mid-2026: 4 buyback filings since 2026-03-09 totaling 240,000 shares (60,000 each on 26 May, 28 May, 2 Jun and 4 Jun 2026, at HK$2.54-2.68). So buybacks span at least late-2025 through June 2026 and are ongoing, with the most recent purchases inside the last two weeks. The amounts are modest relative to the ~693m share count, so the net effect is a slight reduction in shares outstanding rather than a dramatic shrink; the share count is roughly flat-to-slightly-down over three years (no evidence of meaningful option-driven dilution). The buyback is a supporting signal to the dividend, not the main event.

Verdict: Returns Capital - a high, rising dividend (~80-90%+ payout) funded by strong operating cash and net cash, plus ongoing share repurchases-and-cancellations, mark this as a shareholder-friendly capital-returner, with the only caveat that the payout is high enough to limit reinvestment flexibility if earnings keep sliding.

SECTION 11: INSIDER ACTIVITIES

Source and caveat. Hong Kong's HKEX Disclosure of Interests portal is gated, so per the governing data policy the MoatMap cross-market database is the sole source for recent insider transactions here (the exchange portal and third-party aggregators return auth-blocked stubs and are not used). ⚠ The MoatMap feed was last scraped 2026-06-06 01:11 UTC (~37 hours before this report), so filings in the last day-plus may be missing.

Recent insider transactions (last 12 months). MoatMap records zero director/officer/substantial-shareholder dealing transactions for 2219.HK over the trailing 12 months. No open-market purchases and no open-market sales by insiders were captured in the window. (The company's own corporate share repurchases are not insider dealing and are covered in Section 10 - those are the only recent share activity on record: 4 buyback filings, 240,000 shares, 26 May-4 Jun 2026.)

Buys. None recorded. There is therefore no insider open-market buying signal to read - neither a bullish cluster nor a single conviction purchase by the chairman or CFO.

Sells. None recorded. There is no insider selling to explain, so no reason-attribution is required.

Ownership context (for interpreting the absence). The company is tightly held by the founding Zhang family - at IPO the founder's children and a niece collectively held a majority-style block (approximately: Zhang Xiaoli ~15.7%, Zhang Bozhou ~14.4%, Zhang Fengsheng ~11.2%, Zhang Junfeng ~11.2%, Zhang Yumei ~1.6%), alongside institutional holders including Highlight Capital-linked vehicles (>14% via Xiamen Chaoxi / Light Medical), Orchid Asia (~12.2%), and Sunshine Insurance entities (~6-7%). A controlling family that is not selling into a price slump is, in itself, a mildly reassuring (if passive) signal; the active capital-return signal comes from the company-level buybacks, not from individual insider trades.

Net assessment. Over the last 12 months there is no individual insider transaction activity on record - net neither buyer nor seller at the personal level. The signal is therefore neutral on insider dealing specifically, with a modestly constructive overlay from (a) the family not trimming and (b) sustained company-level buybacks-and-cancellations through mid-2026. Read this as the absence of a negative rather than the presence of a strong positive. (Caveat: feed is ~37h stale; a very recent filing could be missing.)

SECTION 12: SCENARIOS

Bull case. China's consumer confidence recovers over the next two to three years, and the elective half of Chaoju's business comes back to life - young professionals resume booking SMILE Pro refractive surgery, parents keep spending on myopia control, and premium optical sells through. At the same time the Yangtze River Delta expansion seasons: the new and acquired coastal hospitals mature past breakeven and start contributing, proving that Chaoju can win outside its Inner Mongolian home turf. The Grade 3A flagships pull in more high-acuity referral cases. The IOL procurement reset annualizes and stops being a drag, with cheaper lenses actually expanding cataract volumes enough to grow the basic segment. Per-patient value keeps climbing as the mix shifts to premium procedures. The company keeps generating strong cash, keeps paying its high dividend, keeps buying back and cancelling stock, and the market re-rates a profitable, net-cash, shareholder-friendly regional champion that has demonstrably broadened beyond one province. In this world Chaoju looks like a smaller, more disciplined, more capital-generous version of the national chains.

Base case. Management roughly delivers what it has guided. The network continues to expand by a handful of hospitals and optical centers a year through a mix of greenfield and bolt-on acquisitions, funded by the undeployed IPO proceeds and internal cash. The home region keeps generating reliable profit and cash; the Yangtze River Delta and North China expansion grows the footprint but contributes modestly to the bottom line as new sites ramp. Revenue stays roughly flat-to-modestly-growing as ASP uplift offsets continued price competition and the lingering effects of IOL pricing reform - much as in FY2025, where strategy execution was good but the macro held results back. The dividend stays high and the buyback continues at a modest pace. It is a steady, cash-generative, slowly-diversifying compounder operating into a difficult-but-improving industry backdrop, with no dramatic re-rating and no blow-up - the business does what it says, and the share count drifts slightly lower.

Bear case. China's consumer weakness persists or deepens, and the discretionary consumer segment keeps shrinking as refractive price wars intensify with Aier and the other chains using scale to undercut. The state extends procurement and pricing pressure beyond IOLs to other basic-segment consumables, squeezing the previously resilient cataract/retina economics. The Yangtze River Delta expansion disappoints - the new hospitals struggle to win share against entrenched competitors, burn cash longer than expected, and acquisitions prove to have been overpaid for, dragging group returns. Surgeon shortages cap the ramp. The high ~90% dividend payout, comfortable while cash flow held, becomes harder to sustain as profit erodes, forcing a cut that breaks the one clear positive in the equity story. Meanwhile the family's use of cash for wealth-management products rather than core reinvestment raises governance questions. In this world Chaoju is a sub-scale regional operator stuck between a dominant national rival and an unyielding state payer, with a shrinking discretionary business and a profit base that no longer comfortably funds its dividend.

Sources

• Chaoju FY2024 Annual Report (HKEXnews PDF)
• Chaoju FY2025 results summary - Minichart
• Chaoju Profit Slips in 2025 as Revenue Declines but Network Expands - TipRanks
• Chaoju Schedules Board Meeting to Approve Annual Results - TipRanks
• About Chaoju - company website
• Chaoju H1 2025 interim investor presentation (company IR PDF, 2025-08-29)
• Chaoju 2025 Interim Report (company IR PDF)
• Chaoju 2025 annual report / high-payout analysis - Stockstar (证券之星)
• Chaoju 2024 results & segment detail - Guancha (观察者网)
• Chaoju H1 2025 segment breakdown - Sina/CICC note
• Chaoju acquisitions & business model - Bamboo Works
• Aier Eye Hospital - Wikipedia (scale/footprint)
• Aier Eye Hospital market cap - companiesmarketcap
• Chengdu Pu Rui / Bright Eye (301239) market cap - StockAnalysis
• Liaoning He Eye (301103) market cap - StockAnalysis
• C-MER Medical (3309.HK) - Stockopedia
• China ophthalmic market sizing - Verified Market Reports
• China ophthalmic devices market - Mordor Intelligence
• IOL volume-based-procurement impact analysis - 21jingji
• Chaoju ownership / pre-IPO shareholder structure - Securities Times (stcn)

Note on completeness: As an HK half-yearly micro-cap, 2219.HK does not publish earnings-call transcripts; the five reporting periods were covered via results announcements and the company's own investor-presentation decks, as disclosed up top. Section 13 (Further Reading) is omitted because SemiAnalysis, Stratechery, and MBI Deep Dives have no coverage of this company. Insider data (Section 11) reflects MoatMap as the sole source for this gated HK venue, last scraped ~37h before this report.